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The present study aimed at reporting on the characteristics, prognostic factors and treatment 
outcomes of 18 cases of nasosinusal mucosa melanoma, and do a literature review on the subject. 
Methods: between 1995 and 2005, 18 patients consecutively diagnosed with nasosinusal mucosa 
melanoma were managed in our institution. We reviewed the literature in PubMed and Scopus in 
order to find the main series from studies associated with this topic. We found a total of 35 series, 
involving 1,077 patients with nasosinusal mucosa melanoma. 
Results: we found 16 men and 2 women, with age at presentation between 51 and 80 years (median 
of 58 years). All these patients were submitted to surgical excision followed by radiotherapy with 
or without chemotherapy. The survival median was 15 months, and the 5-year general survival 
had a percentage value of 23%. Considering our univariate analysis: tumor staging and complete 
remission after initial treatment were deemed relevant prognostic factors. Nonetheless, considering 
the multivariate analysis, only disease stage was statistically significant. 
Conclusion: nasosinusal melanoma is a rare and aggressive tumor, with high loco-regional and 
distant failure rates, and poor treatment outcomes. Notwithstanding, in a literature review we 
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INTRODUCTION
Mucosal melanoma is a highly aggressive tumor 
arising from the mucosa of the head and neck, anorectal 
and genitourinary system. The incidence of mucosal me-
lanoma is believed to be stable, contrary to its counterpart 
the cutaneous melanoma that has been rapidly increasing. 
Primary mucosal melanoma of the head and neck is a 
rare entity, occurring much less frequently that its cuta-
neous relatives and accounts for 1.3% of all malignant 
melanomas. However; head and neck region is the most 
frequent primary site for mucosal melanomas and consists 
of 55.4% of all mucosal melanomas.1 Among head and 
neck anatomical locations, sinonasal tract is a common 
primary site for this malignancy.2, 3 The mean age of pre-
sentation in patients with sinonasal mucosal melanoma is 
approximately 67 years, but it can occur at any age group 
and is extremely rare in ages below 30.1 It has been sug-
gested to have a slight predilection for males as reported 
by some authors.4 Approximately 19-26.6% of patients 
with head and neck mucosal melanomas have positive 
regional lymph nodes at presentation.1, 4 The presence of 
positive lymph nodes in sinonasal mucosal melanomas 
has been considered as a poor prognostic factor in some 
studies.1, 5, 6 The treatment of choice in mucosal malignant 
melanoma is surgery followed by radiotherapy, particu-
larly in cases of small or doubtful margins of resection.7 
The prognosis of mucosal malignant melanoma is poor 
with 0% to 50% of 5-year survival.1, 7, 8 Herein, we describe 
18 cases of sinonasal mucosal melanoma and review the 
major previous reported series including more than 1000 
patients with sinonasal mucosal melanoma. 
METHODS
The study was based on the data collection of 
Radiation Oncology Department, Namazi Academic Hos-
pital, Shiraz University of Medical Sciences.This retrospec-
tive study was performed by reviewing patients’ records 
from our departmental computer databases or from writ-
ten patient lists. Eighteen consecutive patients diagnosed 
with primary mucosal melanoma of the sinonasal tract 
who were treated and followed up in our institution be-
tween 1995 and 2005, were selected for the present study. 
The study included all patients with histopathologically 
proven diagnosis of mucosal melanoma of the sinonasal 
tract. The diagnoses of the cases were confirmed by the 
presence of melanin and/or immunoreactivity to a me-
lano associated markers (S-100 and HMB-45). Metastatic 
lesions arising from disseminated cutaneous or mucosal 
melanomas of any other site were excluded. The staging 
of all cases was determined according to the following 
basic staging system: The lesions confined to the primary 
site were defined as stage I, regional cervical lymph node 
involvement as stage II, and distant metastasis as stage 
III. Clinical data were reviewed to gather the patients’ 
characteristics, prognostic factors and treatment outco-
mes. We performed a literature review of PubMed and 
Scopus using the search terms of “mucosal melanoma” 
and “sinonasal” and/or “nasal cavity” and/or “paranasal 
sinuses” to find out the references for the present study. 
Case series including at least 6 cases over the last 20 years 
were included for the present review. All case reports and 
few articles in non-English language or with unavailable 
full text were excluded. In all, we found 35 series inclu-
ding 1077 patients with sinonasal mucosal melanoma. 
RESULT
The medical records of 18 patients diagnosed as 
having mucosal melanoma of the sinonasal tract, and 
treated at our institution between 1995 and 2005, were 
reviewed. This number contributed 12% of all sinonasal 
malignancies and 2.6% of all malignant melanomas in 
the study period. The mean and median age at diagnosis 
was 65 years (range 51- 80 years), and 16 (87/5%) were 
men. The most common symptoms at presentation were 
epistaxis and nasal obstruction and discharge. Nasal cavity 
(62%) was the most frequent primary site, followed by 
ethmoidal sinuses (19%) and maxillary sinuses (19%). 
The median tumor size was 4 cm (range 2-7 cm). Based 
on the common basic staging system for the mucosal 
melanoma, eight patients had stage I (no evidence of 
regional or distant metastasis) 7 patients had stage II (re-
gional lymph node metastasis) and 3 patients had stage 
III (distant metastatic disease). A combination of excision 
followed by external beam radiotherapy was used to treat 
all cases. All patients received external beam radiothe-
rapy using cobalt-60 units or 9 MV X-ray photons from 
a linear accelerator. A mean dose of 53 Gy (range 20-70 
Gy) was delivered via a daily fraction of 2 Gy, with five 
fractions per week. Five (28%) patients received a median 
2 (range 1-6) cycles of single-agent chemotherapy with 
dacarbazine 850 mg/m2.  
At the last follow-up, 6 cases (33%) were alive with 
no evidence of disease (follow-up range, 3-65 months), 
9 cases (50%) died of disease and the median time to 
death for these patients were 15.6 months (range, 15-17 
months) and 3 patients (17%) are alive with disease. 
The overall cancer specific survival rate was 68.7% at 1 
year, 45.8% at 2 years and 22.9% at 5 years. Disease-free 
survival was 51.3% at 1 year, 25.6% at 2 years and 12.8% 
at 5 years. The median survival was 15 months (range 
3-65 months). Local recurrence was observed in 9 (50%) 
patients; 3 (16.7%) cases had a recurrence in the first 6 
months after treatment, and 9 (50%) cases had a recurren-
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ce 6 months to 3 years after treatment. The median time 
to local recurrence was 11 months (range 2-14 months). 
Distant metastases developed in 3 patients (16.7%). The 
median time from diagnosis of sinonasal melanoma to 
distant metastases was 6 months (range 7-9 months) and 
the median time to death after metastasis was 6 months. 
Various prognostic factors including age, sex, stage of 
disease, initial complete remission, total dose of radio-
therapy and the size of primary tumor were analyzed to 
establish their effect on patient overall survival. On univa-
riate analysis for overall survival, stage of disease (hazard 
ratio for death = 5.794; 95 per cent CI = 1.645-20.408; p 
= 0.006) and initial complete remission to the treatment 
(hazard ratio = 13.409; 95 per cent CI = 1.565-114.920; p 
= 0.018) were prognostic factors. On multivariate analysis, 
only stage of disease (hazard ratio = 22.170; 95% CI = 
1.660-296.061; p = 0.019) retained statistical significance.
DISCUSSION
Malignant neoplasms of the sinonasal tract are rare 
and account for about 3% of head and neck malignant 
tumors. Sinonasal malignancies comprise a heterogeneous 
and biologically diverse group of neoplasms occurring in 
the sinonasal tract.9,10,11 Primary sinonasal mucosal me-
lanoma is a rare entity, which constitutes about 1.5-9% 
of all malignancies in this site.12, 13 Sinonasal melanoma 
tends to have a high rate of locoregional and distant fai-
lure and to carry poor outcome with a median survival 
of 9-52 months and an overall 5-year survival rate of 0% 
to 50%.4-8, 14-42 To date, more than one thousand cases of 
sinonasal melanomas have been reported in the litera-
ture.4-8, 14-42 Sinonasal mucosal melanoma is a tumor that 
usually occurs in the seventh decade of life and rarely 
before the fourth decade, as found in our study. In the 
present study, the mean and median age of our patients 
was 65 years, which is consistent with the results of 
the literature review in which average mean age of 683 
patients in the reported series was 64.5 years. [Table 1] 
There are conflicting reports regarding the incidence of 
sinonasal mucosal melanoma in males and females.6, 8, 26, 
40-43 The male/female ratio of our patients was 8, which 
is consistent with the study by Richtig et al.6 However, in 
the literature review, by analyzing the data of the reported 
series, the mean male/female ratio of 843 patients was 
1.07 and we did not find significant differences. [Table 1] 
Epistaxis and nasal obstruction were the most 
frequent presenting symptoms in our and most other 
reported series.4, 14, 16, 27, 36, 43 There are divergent reports 
concerning the rate of cervical lymph node involvement 
at presentation in patients with sinonasal melanomas. The 
incidence of positive lymph nodes in our study was 44% 
(all patients with stage II and one patient with stage III). 
In a review by Manolidis, 18.7% of patients with malignant 
mucosal melanoma of the head and neck presented with 
cervical lymph node metastasis.4 In the national cancer 
data base report on cutaneous and noncutaneous mela-
noma by Chang et al, this incidence was 26.6%.1 In the 
reported series by Temam et al, only 5 (11%) patients 
had positive lymph node at presentation.20 In contrast, 
Guzzo reported 52% of patients with regional lymphatic 
metastasis at the time of diagnosis.38 Furthermore, there 
are conflicting reports on the subject of the prognostic 
impact of regional lymph node metastasis at presentation 
on survival. Shah et al concluded that regional lymphatic 
metastases do not impact on the survival in patients with 
mucosal melanoma of the head and neck.43 However; 
most large reported series demonstrated that the presence 
of positive lymph nodes in these patients have a nega-
tive influence on disease free and overall survival.1, 21, 27, 
37 In a review by Manolidis, the 5-year overall survival 
of patients with positive lymph node was 21.4% against 
30% for patients with negative lymph node.4 
The majority of patients with mucosal melanoma 
present in stage I disease. Based on the review of the 
reported series by Manolidis, of 547 patients, 75.3% 
presented with stage I, 18.1% with stage II and 6.6 % 
with stage III. In the present study, these values were 
44% for stage I, 39% for stage II and 17% for stage III. 
Sinonasal mucosal melanoma tends to have high rate of 
locoregional recurrence following the initial treatment. 
Despite large proportion of patients presented in stage I 
disease, the rates of locoregional recurrence and distant 
metastases are high. As mentioned by Manolidis, of 484 
patients in 14 series, 53.3% developed locoregional re-
current disease. In addition, Manolidis found an average 
of 51.5% distant failure among 332 patients with mucosal 
melanoma.4 In agreement with the findings of this re-
view, most recent studies found a rate of 40% to 85% for 
locoregional recurrent disease. Most locoregional failure 
occurred within the first 24 months after the treatment.2, 6, 
7, 15, 17, 25, 32, 40, 42 Furthermore, 25% to 77% of all patients in 
recent reported series developed distant failure following 
the initial treatment. Similarly, the most distant failures 
occurred within 2 years.2, 6, 7, 14, 15, 17, 25, 32, 40, 42 
The median time from locoregional recurrent 
disease to death is 19-75 months in reported series. In 
addition, the median time from distant failure to death is 
3-20 months in these studies.2, 7, 16, 18, 19 In our study, the 
median times to local and distant failure were 11 mon-
ths and 6 months, respectively.  Moreover, the median 
times from local and distant failure to death were 12 and 
6 months, respectively. According to the pooled data 
from 20 series, we found a median 25.8 months for 605 
patients with sinonasal mucosal melanoma. In addition, 
by analyzing the pooled data from 31 series, we found 
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Table 1. Patients’ characteristics and median and 5-year overall survival in major reported series
Authors No of patients Male/Female ratio Mean age
Median survival 
(month)
5-year overall survival 
(%)
Manolidis4 13 1,1 71 31 14
McLean5 22 - 67 12 10
Richtig6 9 8 62 30 -
Ziółkowska 8 6 0,2 69 - 50
Huang14 15 1,1 69 23 33
Wagner15 17 2,1 68 - 28
Dauer16 61 1 67 - 22
Pomar Blanco17 6 0,5 70 - 33
Peng18 44 - - 24 25
Martin19 20 0,7 77 23 5
Prasad20 59 1 63 36 35
Temam21 46 1,1 58 - 20
Thompson22 115 0,9 64 28 35
Oueslati23 10 1 58 18 6
Slavícek24 13 - - 9 -
Ryuto25 12 0,5 61 20 22
Diaz Molina26 17 0,4 74 - 36
Cheng27 23 2,3 68 20 22
Regauer28 14 - 68 9 -
Folz29 28 - 67 - 46
Brandwein30 25 0,7 65 39 40
Bridger31 27 1,3 66 52 46
Patel32 35 1,3 63 - 47
Faye-Lund33 13 0,6 72 - -
Nandapalan34 178 - - - 45
Kingdom35 17 - - - 20
Lund36 58 1,1 64 21 28
Bachar37 49 0,5 68 28 29
Gaze38 23 0,6 69 14 -
Guzzo39 26 2,4 58 20 21
Owens40 11 4,5 55 - 33
Hyodo41 14 0,4 64 - 20
Marco Meleti42 25 0,7 67 - 0
Kumar43 10 2,3 51 25 40
Nakaya44 16 2,2 65 - 31
Present study 18 8 65 15 23
Total 1095 1,07 64,5 25,8 31
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an overall 5-year survival rate of 31% for 1023 patients 
in these series. Although this 5-year survival is poor, it 
shows a significant improvement compared with the 
results of the previous literature review by Manolidis, in 
which the 5-year overall survival was 17.1%.  Part of this 
survival improvement may be due to use of multimodality 
therapy for these patients.4 The median survival of our 
patients was 15 months and with a 5-year overall rate of 
23%. The lower median and 5-year overall survival rates 
of our patients may be due to a larger proportion of cases 
with stage II and III compared with other series. Optimal 
treatment of sinonasal mucosal melanoma remains a 
challenge. Complete surgical excision is the mainstay of 
definitive therapy for localized disease with or without 
regional lymph node metastases.3 Postoperative radio-
therapy is usually considered for the majority of patients 
with sinonasal mucosal melanoma.16, 34, 40 The role of 
postoperative adjuvant radiotherapy in the treatment of 
sinonasal mucosal melanoma remains unclear.44-46 Seve-
ral reports concluded that the addition of radiotherapy 
to surgical excision conferred a local control advantage 
even for patients with small tumors. Additionally, there 
are a few reports, which suggest an improvement in sur-
vival for patients receiving postoperative radiotherapy.35, 
47 Although most reported series and reviews found no 
survival benefit from postoperative radiotherapy,2, 19, 21, 34, 
40 many authors recommended aggressive local therapy 
with adjuvant or salvage radiotherapy for patients with 
sinonasal mucosal melanoma, even in the absence of a 
survival benefit.36, 48, 49 Despite aggressive locoregional 
therapy, the majority of patients with sinonasal mucosal 
melanoma eventually die from distant failure and the 
outcomes for these patients in almost all studies have 
remained dismal. Management of disseminated melanoma 
is a challenge because of a paucity of effective systemic 
treatment.50 In an effort to improve systemic disease con-
trol and survival, adjuvant and palliative chemotherapy 
has been widely used.3 Dacarbazine monochemotherapy 
with a single dose of 850-1000 mg/m2 or a multiple dose 
regimen of 250 mg/m2 for 5 days per cycle is currently 
considered the standard first-line treatment in patients 
with advanced malignant melanoma.51, 52 The conventio-
nal systemic treatment modalities such as chemotherapy 
and immunotherapy are disappointing.53 Current studies 
have been focused on the molecular-based therapeutic 
strategies to find out the novel and emerging compounds 
such as growth factor and enzyme inhibitors, and antian-
giogenic and immunomodulatory drugs.54
Prognostic variables were evaluated in many re-
ported series. On univariate analysis, the size and loca-
tion of primary tumor, stage of disease, sex, melanosis, 
postoperative radiotherapy and complete remission have 
been prognostic factors in some studies. However, on 
multivariate analysis, melanosis, younger age (less than 
50 years) and early disease stage were favorable prog-
nostic factors for overall survival.16, 21, 37, 46 In the present 
study, on univariate analysis for overall survival, stage of 
disease and initial complete remission to the treatment 
were prognostic factors. On multivariate analysis, only 
stage of disease retained statistical significance. 
CONCLUSION
The patients’ characteristics, prognostic factors and 
outcome of this study were consistent with the most re-
cent reported series. Based on the findings of the present 
study and those of previous research in the literature, we 
found that sinonasal mucosal melanoma is a rare, but 
highly malignant tumor. This aggressive tumor mostly 
affected patients in the 6th to 8th decades of life with no 
sex predilection. Sinonasal mucosal melanoma tends 
to have a high rate of locoregional and distant failure 
and to carry poor outcome after the current treatment 
and with a median survival of 25.8 months and overall 
5-year survival rates of 31%. However, this review shows 
significant improvement in terms of 5-year survival for 
recent series compared with previously reported series. 
Complete surgical excision is the mainstay of definitive 
therapy for locoregional disease.  Postoperative adju-
vant radiotherapy improves the locoregional control in 
patients with sinonasal mucosal melanoma.  The impact 
of adjuvant radiotherapy and chemotherapy on survival 
remains to be defined. 
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